CTRI/2020/03/024026 [Registered on: 18/03/2020] Trial Registered Prospectively
Last Modified On:
18/10/2021
Post Graduate Thesis
No
Type of Trial
Interventional
Type of Study
Drug
Study Design
Randomized, Parallel Group, Active Controlled Trial
Public Title of Study
Bimatoprost ophthalmic solution 0.01% in patient with chronic open-angle glaucoma or ocular hypertension in both eyes.
Scientific Title of Study
A Randomized (1:1), double-masked, multi-center, two-treatment, single-period, parallel design, multiple dose, comparative study with clinical endpoint of Bimatoprost ophthalmic solution 0.01% of Mankind Pharma Limited, India with LUMIGAN® (Bimatoprost ophthalmic solution) 0.01% of Allergan, Inc., Irvine, CA 92612, U.S.A in patient with chronic open-angle glaucoma or ocular hypertension in both eyes.
Trial Acronym
NA
Secondary IDs if Any
Secondary ID
Identifier
CBCC/2019/020, Version No. 1.0 Protocol Date 09/Jan/2020
Protocol Number
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
Name
Dr Sandeep Singh
Designation
Director Operations
Affiliation
CBCC Global Research LLP
Address
Clinical Operations Department, Room Number 2, East Wing, Second Floor Skoda House Opposite L J Campus S G Highway Sarkhej Ahmedabad – 382210, India
Ahmadabad GUJARAT 382210 India
Phone
9637555304
Fax
9726434204
Email
sandeep.singh@cbccusa.com
Details of Contact Person Scientific Query
Name
Dr Sandeep Singh
Designation
Director Operations
Affiliation
CBCC Global Research LLP
Address
Clinical Operations Department, Room Number 2, East Wing, Second Floor Skoda House Opposite L J Campus S G Highway Sarkhej Ahmedabad – 382210, India
Ahmadabad GUJARAT 382210 India
Phone
9637555304
Fax
9726434204
Email
sandeep.singh@cbccusa.com
Details of Contact Person Public Query
Name
Dr Sandeep Singh
Designation
Director Operations
Affiliation
CBCC Global Research LLP
Address
Clinical Operations Department, Room Number 2, East Wing, Second Floor Skoda House Opposite L J Campus S G Highway Sarkhej Ahmedabad – 382210, India
Ahmadabad GUJARAT 382210 India
Phone
9637555304
Fax
9726434204
Email
sandeep.singh@cbccusa.com
Source of Monetary or Material Support
Mankind Pharma Limited,
208, Okhla Industrial Estate, Phase-3,
New Delhi-110020, India
Primary Sponsor
Name
Mankind Pharma Limited
Address
208, Okhla Industrial Estate, Phase-3,
New Delhi-110020, India
Bimatoprost ophthalmic solution 0.01% of Mankind Pharma Limited, India.
Dose: 0.01%, Frequency: Once Daily, Route of administration: Ocular(Topical), Duration of therapy: 42 Days
Comparator Agent
LUMIGAN® (Bimatoprost ophthalmic solution) 0.01% of Allergan, Inc., Irvine, CA 92612, U.S.A.
Dose: 0.01%, Frequency: Once Daily, Route of administration: Ocular(Topical), Duration of therapy: 42 Days
Inclusion Criteria
Age From
18.00 Year(s)
Age To
65.00 Year(s)
Gender
Both
Details
The subjects must meet all of the following inclusion criteria:
1. Patient willing and able to provide voluntary informed consent and to follow the protocol requirements.
2. Male and female patient aged Greater or equal to18 years having body mass index BMI Greater or equal to 17 calculated as weight in kg per height in m2.
3. Patients with chronic open angle glaucoma or ocular hypertension in both eyes.
4. Patient requires treatment of both eyes and is able to discontinue use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.
5. Adequate wash-out period prior to baseline of any ocular hypotensive medication as per the table below. In order to minimize potential risk to patients due to intraocular pressure IOP elevations during the washout period, the investigator may choose to substitute a parasympathomimetic or carbonic anhydrase inhibitor in place of a sympathomimetic, alpha-agonist, beta-adrenergic blocking agent, or prostaglandin; however, all patients must have discontinued all ocular hypotensive medication for the minimum washout period provided below
a. Parasympathomimetics [e.g., pilocarpine, carbachol] - 4 days
b. Carbonic anhydrase inhibitors (systemic or topical) [e.g., acetazolamide, dorzolamide hydrochloride, brinzolamide] - 4 days
c. Sympathomimetics [e.g., dipivefrin, epinephrine] - 2 weeks
d. Alpha-agonists [e.g., apraclonidine, brimonidine tartrate, brimonidine tartrate and brinzolamide] - 2 weeks
e. Beta-adrenergic blocking agents [e.g., timolol, timolol maleate and dorzolamide hydrochloride, timolol maleate and brimonidine tartrate, levobunolol, betaxolol, metipranolol, carteolol] - 4 weeks
f. Prostaglandin analogs (e.g., latanoprost, travoprost, bimatoprost, tafluprost] - 4 weeks
g. Osmotic agents - 4 days
6. Baseline (Day 0/hour 0) IOP Greater or equal to 22 mm Hg and Less than or equal to 34 mm Hg in each eye and difference between IOP in the left and right eye is not greater than 5 mm Hg.
7. Baseline best corrected visual acuity equivalent to 20/200 (6/60) or better in each eye.
8. Women of child bearing potential, (defined as women physiologically capable of becoming pregnant, unless they are using effective method of contraception during dosing of the investigational product) practicing any two acceptable methods of contraception.
Acceptable methods of contraception are:
a. Oral or parenteral (injection, patch or implant) hormonal contraception which has been used continuously for at least one month prior to the first dose of study medication
b. Intrauterine deviceIUD or intrauterine system IUD or IUS
c. Double barrier method of contraception Condom and occlusive cap or condom and spermicidal agent
d. Male sterilization (at least 6 months prior to the screening, should be the sole male partner for that patient)
e. Female sterilization (surgical bilateral oophorectomy) or tubal ligation at least 6 weeks prior to study participation
f. Total abstinence, partial abstinence is not acceptable.
No history of addiction to any recreational drug or drug dependence or alcohol addiction.
ExclusionCriteria
Details
The subjects must not meet any of the following exclusion criteria:
1. Hypersensitivity to Bimatoprost or related class of drugs or to any of the excipients of the formulation.
2. Current or history within two months prior to baseline of any other significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye.
3. Corneal abnormalities that would prevent accurate IOP readings with the Goldmann applanation tonometer.
4. Functionally significant visual field loss.
5. Use at any time prior to baseline of an intraocular corticosteroid implant.
6. Use of contact lens within one week prior to baseline.
7. Use within two weeks prior to baseline of: 1) topical ophthalmic corticosteroid, or 2) topical corticosteroid
8. Use within one month prior to baseline of: 1) systemic corticosteroid or 2) high-dose salicylate therapy defined as 325mg taken on three consecutive days.
9. Use within six months prior to baseline of intravitreal or subtenon injection of ophthalmic corticosteroid.
10. Underwent within six months prior to baseline any other intraocular surgery (e.g., cataract surgery)
11. Underwent within twelve months prior to baseline: refractive surgery, filtering surgery or laser surgery for IOP reduction
12. Amblyopia - only one sighted eye
13. Severe retinal disease or other severe ocular pathology, such as glaucomatous damage with a cup/disk ratio greater than 0.8, split fixation, or functionally significant (in the investigators’ opinion) visual field loss
14. Chronic use of any systemic medication that may affect IOP with less than three month stable dosing regimen (i.e., sympathomimetic agents, beta-adrenergic blocking agents, alpha agonists, alpha-adrenergic blocking agents, calcium channel blockers, angiotensin -converting enzyme inhibitors, etc.)
15. History or presence of any uncontrolled debilitating systemic disease (e.g. cardiovascular disease, hypertension, diabetes mellitus, hepatic impairment etc.)
16. History of recurrent ocular seasonal allergies within the past 2 years
17. Patients with positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV).
18. Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the patient to participate in the study that would limit adherence to study requirements
19. Participation in any clinical study within 90 days before the first dose of Investigational Product.
20. Pregnant or lactating woman.
Method of Generating Random Sequence
Computer generated randomization
Method of Concealment
Pre-numbered or coded identical Containers
Blinding/Masking
Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded
Primary Outcome
Outcome
TimePoints
Mean difference in intraocular pressure (IOP) of both eyes between the two treatment groups
Day: 00, Day: 14 ± 3, Day : 42 ± 3 - 00.00 hour (between 8:00 am and 10:00 am), 04.00 hours (at 4 hours ± 30 minutes after 00.00 hours), 08.00 hours (at 8 hours ± 30 minutes after 00.00 hours)
Secondary Outcome
Outcome
TimePoints
Incidence of treatment-emergent serious and non-serious adverse events (AEs)
Day: 00, Day: 14 ± 3, Day : 42 ± 3 - 00.00 hour (between 8:00 am and 10:00 am), 04.00 hours (at 4 hours ± 30 minutes after 00.00 hours), 08.00 hours (at 8 hours ± 30 minutes after 00.00 hours)
Target Sample Size
Total Sample Size="48" Sample Size from India="48" Final Enrollment numbers achieved (Total)= "61" Final Enrollment numbers achieved (India)="61"
Individual Participant Data (IPD) Sharing Statement
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Brief Summary
A Randomized (1:1),
double-masked, multi-center, two-treatment, single-period, parallel design,
multiple dose, comparative study with clinical endpoint of Bimatoprost
ophthalmic solution 0.01% of Mankind Pharma Limited, India with LUMIGAN®
(Bimatoprost ophthalmic solution) 0.01% of Allergan, Inc., Irvine, CA 92612,
U.S.A in patients with chronic open-angle glaucoma or ocular hypertension in both
eyes.
Primary Objective: To compare Bimatoprost
ophthalmic solution 0.01% of Mankind Pharma Limited, India with LUMIGAN®
(Bimatoprost ophthalmic solution) 0.01% of Allergan, Inc., Irvine, CA 92612,
U.S.A
Secondary
Objective: To monitor the adverse events and to ensure
the safety of patients.